HIF2α-IN-2 ( TCS 7009 | TC S 7009 | TC-S 7009 )

产品货号. M11779 CAS No. 1422955-31-4

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

拼团产品询价大包装询价加入购物车

产品名称

HIF2α-IN-2
注意事项

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
产品简述

HIF2α-IN-2 是一种有效的、选择性的 HIF-2α PAS-B 结构域变构抑制剂，Kd 为 81 nM。
产品描述

HIF2α-IN-2 is a potent, selective, allosteric inhibitor of HIF-2α PAS-B domain with Kd of 81 nM, shows high selectivity and does not affect HIF-1 function; antagonizes HIF-2 heterodimerization and DNA-binding activity in vitro and in cultured cells, reducing HIF-2 target gene expression.
体外实验

Cell Proliferation Assay Cell Line:HPF cells in hypoxic conditions Concentration:0-100?μM Incubation Time:72 hours Result:Showed greater inhibition of cell proliferation in hypoxic conditions than that in normoxic conditions.
体内实验

——
同义词

TCS 7009 | TC S 7009 | TC-S 7009
通路

Angiogenesis
靶点

HIF/HIF Prolyl-hydroxylase
受体

HIF/HIF Prolyl-hydroxylase
研究领域

——
适应症

——

1. Scheuermann TH, et al. Nat Chem Biol. 2013 Apr;9(4):271-6.

计算器

产品手册

关联产品

Vadadustat

Vadadustat (PG-1016548, AKB-6548) 是一种新型、有效、口服活性的 HIF-PH 抑制剂，正在开发中，用于治疗非透析依赖性 (NDD) 和透析依赖性 CKD 患者的贫血。
TAT-cyclo-CLLFVY

Selective HIF-1 dimerization inhibitor. Blocks protein-protein interaction of recombinant HIF-1α, but not HIF-2α, with HIF-1β (IC50 = 1.3 μM). Inhibits hypoxia-induced HIF-1 activity, and decreases VEGF and CAIX expression in osteosarcoma and breast cancer cells in vitro. Also reduces tubularization of hypoxic HUVECs.
TP-0463518

TP-0463518 是一种新型高效 HIF 脯氨酰羟化酶 (PHD) 抑制剂。